Loading...
RDNT logo

RadNet, Inc.NasdaqGM:RDNT Rapport sur les actions

Capitalisation boursière US$4.1b
Prix de l'action
US$54.17
US$89.88
39.7% sous-évalué décote intrinsèque
1Y-10.7%
7D-3.1%
Valeur du portefeuille
Voir

RadNet, Inc.

NasdaqGM:RDNT Rapport sur les actions

Capitalisation boursière : US$4.1b

RadNet (RDNT) Aperçu de l'action

RadNet, Inc. et ses filiales fournissent des services d'imagerie diagnostique ambulatoire aux États-Unis et dans le monde entier. Plus de détails

RDNT analyse fondamentale
Score flocon de neige
Évaluation4/6
Croissance future4/6
Performances passées0/6
Santé financière3/6
Dividendes0/6

RDNT Community Fair Values

Create Narrative

See what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.

RadNet, Inc. Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 RadNet
Historique des cours de bourse
Prix actuel de l'actionUS$54.17
Plus haut sur 52 semainesUS$85.84
Plus bas sur 52 semainesUS$50.76
Bêta1.43
Variation sur 1 mois-10.30%
Variation sur 3 mois-23.79%
Variation sur 1 an-10.70%
Variation sur 3 ans92.98%
Variation sur 5 ans107.95%
Évolution depuis l'introduction en bourse5,317.00%

Nouvelles et mises à jour récentes

Article d’analyse May 14

Analysts Have Made A Financial Statement On RadNet, Inc.'s (NASDAQ:RDNT) First-Quarter Report

Last week, you might have seen that RadNet, Inc. ( NASDAQ:RDNT ) released its quarterly result to the market. The early...
Mise à jour du récit May 07

RDNT: Imaging Platform Execution And New Idaho Venture Will Support Future Earnings

Analysts have trimmed their fair value estimate for RadNet by $0.50 to $89.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E after recent Street research, including a lower $4 price target from B. Riley and an upgrade of Lumexa Imaging at Raymond James.
Mise à jour du récit Apr 23

RDNT: Sector Sentiment Tailwinds Will Support Future Earnings Visibility

Analysts have trimmed their price target on RadNet by $2 to reflect slightly updated assumptions on fair value, future P/E and operating metrics, while incorporating recent Street research that highlights improved sentiment following the Raymond James upgrade of Lumexa Imaging. Analyst Commentary Bullish Takeaways Bullish analysts view the recent upgrade of Lumexa Imaging as a supportive read-through for sentiment around diagnostic imaging.

Recent updates

Article d’analyse May 14

Analysts Have Made A Financial Statement On RadNet, Inc.'s (NASDAQ:RDNT) First-Quarter Report

Last week, you might have seen that RadNet, Inc. ( NASDAQ:RDNT ) released its quarterly result to the market. The early...
Mise à jour du récit May 07

RDNT: Imaging Platform Execution And New Idaho Venture Will Support Future Earnings

Analysts have trimmed their fair value estimate for RadNet by $0.50 to $89.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E after recent Street research, including a lower $4 price target from B. Riley and an upgrade of Lumexa Imaging at Raymond James.
Mise à jour du récit Apr 23

RDNT: Sector Sentiment Tailwinds Will Support Future Earnings Visibility

Analysts have trimmed their price target on RadNet by $2 to reflect slightly updated assumptions on fair value, future P/E and operating metrics, while incorporating recent Street research that highlights improved sentiment following the Raymond James upgrade of Lumexa Imaging. Analyst Commentary Bullish Takeaways Bullish analysts view the recent upgrade of Lumexa Imaging as a supportive read-through for sentiment around diagnostic imaging.
Mise à jour du récit Apr 08

RDNT: Outpatient Imaging Shift Will Support Future Earnings Visibility

RadNet's analyst price target now stands at $92. Analysts cite outpatient diagnostic imaging growth drivers, Medicare reimbursement support, potential capital deployment, and an AI ramp as key reasons for maintaining this level.
Mise à jour du récit Mar 25

RDNT: Outpatient Imaging Shift And AI Adoption Will Drive Future Upside

Analysts kept their $92 price target for RadNet unchanged, citing what they see as attractive long term growth drivers in outpatient diagnostic imaging, reasonable 2025 to 2028 company targets, supportive Medicare reimbursement trends, potential capital deployment benefits, and expected AI contributions. Analyst Commentary Bullish Takeaways Bullish analysts view outpatient diagnostic imaging as an attractive subsector, with hospital to outpatient shifts and growing demand for advanced imaging seen as key growth drivers that support RadNet's long term story and current valuation framework.
Mise à jour du récit Mar 09

RDNT: Outpatient Imaging Shift And AI Ramp Will Support Future Upside

Analysts have raised their price target on RadNet from $91.75 to $92.38. The updated target reflects revised assumptions that incorporate higher projected revenue growth, a lower profit margin outlook, and a higher future P/E multiple supported by recent bullish Street research on outpatient imaging and AI benefits.
Mise à jour du récit Feb 22

RDNT: Outpatient Imaging Shift And AI Adoption Will Support Future Upside

Analysts have trimmed their implied future P/E assumption for RadNet, leading to a slightly lower blended price target of about $97 vs. roughly $102 previously.
Mise à jour du récit Feb 08

RDNT: Outpatient Imaging Shift And AI Breast Screening Will Support Upside

Analysts have raised their price target on RadNet to about $92, reflecting confidence in the outpatient diagnostic imaging segment and the company's 2025 to 2028 targets, including expected benefits from improved Medicare rates, potential capital deployment, and increasing AI contributions. Analyst Commentary Recent research reflects a generally constructive tone on RadNet, with several firms lifting price targets into the high US$80s to low US$90s range and highlighting both the core imaging business and longer term AI potential.
Mise à jour du récit Jan 24

RDNT: Outpatient Imaging Shift And AI Breast Screening Will Drive Upside

Analysts lifted their price target on RadNet to about US$91.75 from roughly US$91.71, reflecting recent coverage that highlights outpatient imaging growth drivers, supportive Medicare reimbursement, capital deployment options, and potential contributions from artificial intelligence (AI). Analyst Commentary Recent Street research on RadNet focuses on outpatient imaging growth, long term targets and the role of AI and capital allocation in supporting the current valuation framework.
Mise à jour du récit Jan 09

RDNT: Outpatient Imaging And AI Adoption Will Drive Future Outperformance

Analysts have raised their price target on RadNet to about US$92, citing what they view as reasonable 2025 to 2028 goals, supportive Medicare reimbursement trends, potential capital deployment upside, and growing contributions from AI and outpatient imaging demand. Analyst Commentary Recent research has focused on how RadNet's outpatient imaging footprint, AI initiatives, and long term financial targets could support its valuation and growth ambitions.
Mise à jour du récit Dec 13

RDNT: Integrated Offerings And Margin Expansion Will Drive Future Outperformance

Analysts have modestly increased their price target on RadNet, citing stronger long term growth and margin expansion prospects highlighted at the recent investor day and reflected in updated fair value estimates rising from about $91.71 to roughly $92.50 per share, alongside reaffirmed expectations for double digit revenue growth and mid teens EBITDA expansion. Analyst Commentary Bullish analysts highlight that the updated 2028 targets for double digit revenue growth and margin expansion underpin a durable mid teens EBITDA growth profile, which they view as supportive of further multiple expansion from current levels.
Mise à jour du récit Nov 28

RDNT: Sustained Demand And Integrated Offerings Will Drive Future Outperformance

Analysts have raised their price target for RadNet from approximately $87 to $93, citing higher revenue growth expectations and confidence in the company’s integrated offerings and sustained demand. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for RadNet, citing encouraging revenue growth expectations and confidence in the company’s ability to deliver sustained margin expansion.
Article d’analyse Nov 14

Earnings Miss: RadNet, Inc. Missed EPS By 65% And Analysts Are Revising Their Forecasts

Shareholders might have noticed that RadNet, Inc. ( NASDAQ:RDNT ) filed its third-quarter result this time last week...
Mise à jour du récit Nov 13

RDNT: Momentum Will Accelerate From Surging Demand And Integrated Offerings

RadNet’s analyst price target has increased from $80.57 to $86.67. This reflects confidence from analysts who cite strong demand, integrated offerings, and positive industry momentum as key drivers.
Mise à jour du récit Oct 30

RDNT: Imaging Center Demand And Digital Health Will Drive Measured Upside Potential

Analysts have increased their price target for RadNet from $74 to $81. They cite strong core imaging center demand and ongoing investments in digital health as key factors for the optimistic outlook.
Mise à jour du récit Oct 15

AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics

RadNet's analyst price target has been raised from $79.29 to $80.57 per share. This change reflects analysts' optimism amid strong imaging center demand, ongoing digital health investments, and potential M&A opportunities.
Mise à jour du récit Sep 19

AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics

RadNet’s consensus price target has risen to $79.29 as analysts cite robust imaging center demand, expanding service opportunities, strong digital health investments, and confidence in management’s strategic execution. Analyst Commentary Robust core imaging center demand trends indicate sustained growth potential.
Article d’analyse Sep 12

RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Mise à jour du récit Sep 04

AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics

Driven by robust imaging center demand, growth opportunities, and strong digital health investments, RadNet’s consensus analyst price target held steady at $77.43. Analyst Commentary Robust core imaging center demand trends highlighted in recent management meetings.
Seeking Alpha Aug 18

RadNet: Bloated Capital Base Not Pulling Its Economic Weight (Rating Downgrade)

Summary I am downgrading RDNT stock to hold due to excessive capital requirements, bloated acquisitions, and declining returns on invested capital despite strong top-line growth. The valuation is stretched, with RadNet trading at 78x EBIT and >5x book value, while debt levels and working capital intensity have surged. Operating margins are compressing, free cash flow yields have turned negative, and acquisitions are not delivering sufficient economic returns. I will reconsider a more bullish stance only if RDNT demonstrates margin expansion, improved capital productivity, or stronger free cash flow generation. Read the full article on Seeking Alpha
Article d’analyse Jul 31

Some Confidence Is Lacking In RadNet, Inc.'s (NASDAQ:RDNT) P/S

When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
Article d’analyse Jul 15

RadNet (NASDAQ:RDNT) May Have Issues Allocating Its Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Article d’analyse Jun 10

We Think RadNet (NASDAQ:RDNT) Is Taking Some Risk With Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Article d’analyse May 15

RadNet, Inc. (NASDAQ:RDNT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Investors in RadNet, Inc. ( NASDAQ:RDNT ) had a good week, as its shares rose 9.8% to close at US$60.34 following the...
Article d’analyse May 07

Is There An Opportunity With RadNet, Inc.'s (NASDAQ:RDNT) 37% Undervaluation?

Key Insights The projected fair value for RadNet is US$84.18 based on 2 Stage Free Cash Flow to Equity Current share...
Article d’analyse Apr 24

Is RadNet, Inc. (NASDAQ:RDNT) Potentially Undervalued?

RadNet, Inc. ( NASDAQ:RDNT ), might not be a large cap stock, but it received a lot of attention from a substantial...
Article d’analyse Apr 11

Returns On Capital Signal Tricky Times Ahead For RadNet (NASDAQ:RDNT)

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Seeking Alpha Mar 11

RadNet: On The Sidelines For Now

Summary RDNT's stock performance has been lackluster, with only an 8.8% increase over the past year, currently trading at $50 per share. Despite decent fundamentals, including steady revenue growth and strong operating cash flow, RDNT faces risks from wage increases and weather-related disruptions. Recent market overreaction to temporary weather impacts presents a potential rebound opportunity, but the projected 8.6% return does not justify the investment risk. I rate RDNT as neutral due to uncertainties in revenue growth and bottom-line pressures, suggesting better opportunities elsewhere with more favorable risk-reward profiles. Read the full article on Seeking Alpha
Article d’analyse Feb 16

There's Reason For Concern Over RadNet, Inc.'s (NASDAQ:RDNT) Price

RadNet, Inc.'s ( NASDAQ:RDNT ) price-to-sales (or "P/S") ratio of 2.6x may not look like an appealing investment...
Article d’analyse Jan 31

A Look At The Fair Value Of RadNet, Inc. (NASDAQ:RDNT)

Key Insights RadNet's estimated fair value is US$73.25 based on 2 Stage Free Cash Flow to Equity Current share price of...
Article d’analyse Jan 16

Does RadNet (NASDAQ:RDNT) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse Jan 01

Is It Time To Consider Buying RadNet, Inc. (NASDAQ:RDNT)?

RadNet, Inc. ( NASDAQ:RDNT ), might not be a large cap stock, but it received a lot of attention from a substantial...
Article d’analyse Nov 12

There's Reason For Concern Over RadNet, Inc.'s (NASDAQ:RDNT) Massive 26% Price Jump

RadNet, Inc. ( NASDAQ:RDNT ) shares have continued their recent momentum with a 26% gain in the last month alone. The...
Article d’analyse Oct 15

Here's What To Make Of RadNet's (NASDAQ:RDNT) Decelerating Rates Of Return

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
Seeking Alpha Oct 02

RadNet: Secular Tailwinds Underpinned By AI Monetization Prospects

Summary RadNet, the largest US diagnostic imaging operator, projects $1.8bn in 2024 revenue, driven by AI and Digital Health growth, and expanding imaging centers. Strong Q2 results with 13.9% revenue growth and 19.7% EBITDA increase, fueled by AI advancements and new imaging center openings. Future growth catalysts include market shifts to freestanding centers, increasing importance of joint ventures, and capital deployment for acquisitions and new facilities. Digital Health and AI initiatives, like DeepHealth OS and EBCD, are expected to drive significant revenue and margin expansion. Read the full article on Seeking Alpha
Article d’analyse Sep 22

Unpleasant Surprises Could Be In Store For RadNet, Inc.'s (NASDAQ:RDNT) Shares

When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
User avatar
Nouveau récit Aug 30

Expanding Imaging Modalities And AI Integration Signal Strong Future Growth In Healthcare Sector

Expansion into advanced imaging and integration of AI technologies aim at boosting revenue through higher reimbursement rates and operational efficiencies.
Seeking Alpha Aug 24

RadNet: Growth In Operating Earnings Off Very Little Incremental Capital

Summary RDNT stock is up 10% since my June publication following a strong set of quarterly numbers in its Q2 FY'24 earnings. Management continue executing on the growth route, recycling funds into new store openings. Same-store procedure volumes continue to ratchet higher, evidencing increased utilization of its legacy base. Net-net, reiterate buy. Read the full article on Seeking Alpha
Article d’analyse Jul 22

RadNet (NASDAQ:RDNT) Seems To Use Debt Quite Sensibly

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse Jun 05

Returns On Capital At RadNet (NASDAQ:RDNT) Have Stalled

To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
Seeking Alpha Jun 05

RadNet: Qualified Growth Route, Still Undervalued

Summary RadNet, Inc. shares continue to show strength, having compounded by 184% since 2022. Q1 FY 2024 earnings showed growth in the Digital Health segment and increased MRI, CT, and PET/CT volumes. Management has increased its outlook on full-year revenues and projects $1.67-$1.7 billion in revenue for the year. Read the full article on Seeking Alpha
Article d’analyse May 10

Is There Now An Opportunity In RadNet, Inc. (NASDAQ:RDNT)?

While RadNet, Inc. ( NASDAQ:RDNT ) might not have the largest market cap around , it received a lot of attention from a...
Article d’analyse Apr 08

Are RadNet, Inc. (NASDAQ:RDNT) Investors Paying Above The Intrinsic Value?

Key Insights Using the 2 Stage Free Cash Flow to Equity, RadNet fair value estimate is US$40.76 RadNet's US$49.04 share...
Article d’analyse Mar 06

RadNet, Inc.'s (NASDAQ:RDNT) 26% Price Boost Is Out Of Tune With Revenues

The RadNet, Inc. ( NASDAQ:RDNT ) share price has done very well over the last month, posting an excellent gain of 26...
Article d’analyse Feb 08

Why RadNet, Inc. (NASDAQ:RDNT) Could Be Worth Watching

RadNet, Inc. ( NASDAQ:RDNT ), might not be a large cap stock, but it received a lot of attention from a substantial...
Seeking Alpha Jan 28

RadNet, Inc. Stock Price Is More Vigorous Than Its Valuation

Summary RadNet, Inc. is assessed as a Buy opportunity especially on price dips for retail value investors; watch its valuation and growth ratings. The company's share price has seen significant growth recently but may drop due to volatility and potential missed estimates. RadNet is at the forefront of the movement to bring diagnostic imaging services out of hospitals, offering lower costs and increased accessibility. Read the full article on Seeking Alpha
Article d’analyse Dec 28

Getting In Cheap On RadNet, Inc. (NASDAQ:RDNT) Might Be Difficult

There wouldn't be many who think RadNet, Inc.'s ( NASDAQ:RDNT ) price-to-sales (or "P/S") ratio of 1.5x is worth a...
Article d’analyse Dec 04

We Think RadNet (NASDAQ:RDNT) Can Stay On Top Of Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Article d’analyse Aug 27

RadNet (NASDAQ:RDNT) Might Be Having Difficulty Using Its Capital Effectively

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
Article d’analyse Aug 09

RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Article d’analyse Mar 30

We Think RadNet (NASDAQ:RDNT) Is Taking Some Risk With Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Rendement pour les actionnaires

RDNTUS HealthcareUS Marché
7D-3.1%2.0%-0.7%
1Y-10.7%10.7%24.4%

Rendement vs Industrie: RDNT a sous-performé le secteur US Healthcare qui a rapporté 10.7 % au cours de l'année écoulée.

Rendement vs marché: RDNT a sous-performé le marché US qui a rapporté 24.4 % au cours de l'année écoulée.

Volatilité des prix

Is RDNT's price volatile compared to industry and market?
RDNT volatility
RDNT Average Weekly Movement6.2%
Healthcare Industry Average Movement7.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Cours de l'action stable: RDNT n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de RDNT ( 6% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
19819,060Howard Bergerwww.radnet.com

RadNet, Inc. et ses filiales fournissent des services d'imagerie diagnostique ambulatoire aux États-Unis et dans le monde entier. La société opère dans deux secteurs, les centres d'imagerie et la santé numérique. Ses services comprennent l'imagerie par résonance magnétique, la tomographie assistée par ordinateur, la tomographie par émission de positons, la médecine nucléaire, la mammographie, l'échographie, la radiologie diagnostique, la fluoroscopie et d'autres procédures connexes, ainsi que des services d'imagerie multimodale.

RadNet, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de RadNet se comparent-ils à sa capitalisation boursière ?
RDNT statistiques fondamentales
Capitalisation boursièreUS$4.12b
Bénéfices(TTM)-US$14.19m
Recettes(TTM)US$2.14b
2.0x
Ratio P/S
-300.1x
Ratio P/E

Le site RDNT est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
RDNT compte de résultat (TTM)
RecettesUS$2.14b
Coût des recettesUS$1.78b
Marge bruteUS$368.93m
Autres dépensesUS$383.13m
Les revenus-US$14.19m

Derniers bénéfices déclarés

Mar 31, 2026

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)-0.18
Marge brute17.20%
Marge bénéficiaire nette-0.66%
Ratio dettes/capitaux propres80.3%

Quelles ont été les performances à long terme de RDNT?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/18 05:16
Cours de l'action en fin de journée2026/05/18 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

RadNet, Inc. est couverte par 12 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Sarah JamesBarclays
Andrew MokBarclays
Yuan ZhiB. Riley Securities, Inc.